Privacy Analytics > Resources > Webinars > “Increase Access to A Global Good” – interview with Vivli’s Dr. Rebecca Li
“Increase Access to A Global Good” – interview with Vivli’s Dr. Rebecca Li
An Executive Conversation with Vivli’s Executive Director Dr. Rebecca Li and Privacy Analytics’ founder Dr. Khaled El Emam.
What is Vivli? Why is it a breakthrough for clinical trials data sharing? In this Executive Conversation, Our Special Guest, Vivli Executive Director Dr. Rebecca Li; and Dr. Khaled El Emam, Founder of Privacy Analytics, discuss the Vivli-Privacy Analytics partnership and its significance for the global health research community.
Rebecca Li, PhD, is the Executive Director of Vivli and on faculty at the Center for Bioethics at the Harvard Medical School. Previous to her current role she was the Executive Director of the MRCT Center of Brigham and Women’s Hospital and Harvard for over 5 years and remains a Senior Advisor at the Center. She has over 25 years of experience spanning the entire drug development process with experience in Biotech, Pharma and CRO environments. She completed a Fellowship in 2013 in the Division of Medical Ethics at Harvard Medical School. She earned her PhD in Chemical and Biomolecular Engineering from Johns Hopkins University.
Rebecca Li, Ph. D.
Executive Director of Vivli
Dr. Khaled El Emam is a Senior Scientist at the Children’s Hospital of Eastern Ontario (CHEO) Research Institute and heads the multi-disciplinary Electronic Health Information Laboratory (EHIL) team, conducting academic research on privacy preserving technologies such as data synthesis, de-identification and re-identification risk measurement, secure computation, and federated analysis. He is also a Professor in the Faculty of Medicine at the University of Ottawa. Khaled (co-)founded six companies focused on data management, data analytics and privacy preserving technologies.
Dr. Khaled El Emam
Founder of Privacy Analytics Inc.
Situation: California’s Consumer Privacy Act inspired Comcast to evolve the way in which they protect the privacy of customers who consent to share personal information with them.
Situation: Integrate.ai’s AI-powered tech helps clients improve their online experience by sharing signals about website visitor intent. They wanted to ensure privacy remained fully protected within the machine learning / AI context that produces these signals.
Situation: Novartis’ digital transformation in drug R&D drives their need to maximize value from vast stores of clinical study data for critical internal research enabled by their data42 platform.
Situation: CancerLinQ™, a subsidiary of American Society of Clinical Oncology, is a rapid learning healthcare system that helps oncologists aggregate and analyze data on cancer patients to improve care. To achieve this goal, they must de-identify patient data provided by subscribing practices across the U.S.
Situation: Needed to ensure the primary market research process was fully compliant with internal policies and regulations such as GDPR.
Situation: Needed to enable AI-driven product innovation with a defensible governance program for the safe and responsible use
of voice-to-text data under Shrems II.
This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.